spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  rHuPH20 

 HSMN NewsFeed - 3 Feb 2025
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT(R)(amivantamab) Co-Formulated with ENHANZE(R) for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Dec 2024
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig(TM) with ENHANZE(R) for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo(R) (nivolumab) Indications
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2024
Halozyme Announces Roche's OCREVUS(R) SC with ENHANZE(R) Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 26 Apr 2022
Halozyme Commences Tender Offer for All Outstanding Shares of Common Stock of Antares Pharma
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 13 Apr 2022
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 12 Jul 2021
Janssen Announces U.S. FDA Approval of DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jun 2021
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE(R) drug delivery technology to enable development of "ultra-long-acting" medicines for HIV
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 6 Oct 2020
Halozyme Announces Expansion Of Collaboration And License Agreement With argenx For ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory
 HSMN NewsFeed - 22 May 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2010
Halozyme Therapeutics Realigns Management
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 May 2010
Halozyme Announces Voluntary Recall of HYLENEX(R)
Biopharmaceuticals Product Recall
 HSMN NewsFeed - 15 Jul 2009
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID with rHuPH20 Enzyme
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2008
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Biopharmaceuticals
 HSMN NewsFeed - 10 Sep 2007
Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 14 Feb 2007
Halozyme Therapeutics and Baxter Present Promising Results for the Use of HYLENEX From the Infuse-Morphine Study
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Halozyme and Roche Enter Agreement for the Application of Enhanze, A Novel Technology to Improve Drug Delivery
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 8 Nov 2006
Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jun 2006
Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Halozyme Therapeutics Announces FDA 510(k) Clearance for MediCult's SynVitro Cumulase Product
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
rHuPH20
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.